PTC Therapeutics, Inc. appointed Pierre Gravier, age 38, as Chief Financial Officer, effective as of July 13, 2023. Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to the Company. From 2013 to July 2023, Mr. Gravier was a managing director in the healthcare group of Perella Weinberg Partners (Perella Weinberg), a leading independent global advisory firm.

At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development. From 2009 to 2013, Mr. Gravier worked as a healthcare investment banker at Barclays Capital in London. In 2008, Mr. Gravier was a Venture Capital Analyst at Société Générale Asset Management in Paris, where he focused on early-stage investments in the biotechnology sector.

Mr. Gravier began his career as a Scientist at Ferring Pharmaceuticals from 2006 to 2007. Mr. Gravier holds a Master?s Degree in Finance from ESCP Business School and a Master of Science in Bioengineering from the University of Technology of Compiègne.